Article

Infectious keratitis responds to riboflavin crosslinking

Corneal collagen crosslinking with ultraviolet A light and riboflavin is promising therapy for infectious keratitis caused by a variety of pathogens, said J. Bradley Randleman, MD.

Chicago-Corneal collagen crosslinking (CXL) with ultraviolet A (UVA) light and riboflavin is promising therapy for infectious keratitis caused by a variety of pathogens, said J. Bradley Randleman, MD.

“More study is needed, and there are a number of questions to be answered,” said Dr. Randleman, associate professor of ophthalmology, Emory University, Atlanta. “However, CXL is exciting, in part because it may also be beneficial for preventing corneal melting in more severe cases and for its implications for improving outcomes where compliance with antibiotic therapy is a potential concern.”

The ability to eradicate pathogens and protect the cornea while doing so by increasing corneal strength and resistance to collagen enzymatic degradation provides the rationale for interest in using CXL as a treatment for infectious keratitis. In vitro experiments have confirmed that the technique is effective against most bacteria and fungi, and independent authors have reported on its efficacy in clinical use for treating infectious keratitis of varying etiologies, including in cases of treatment-resistant Acanthamoeba keratitis. In a pilot study investigating CXL as primary therapy for microbial keratitis, Mortensen et al. reported complete resolution after a single treatment in 14 of 16 eyes.

Questions that need to be answered include whether CXL should be used as a primary intervention or reserved for eyes that have failed antibiotic therapy, if it can be used as solo treatment or should be adjuvant therapy, and whether it is repeatable if a first treatment fails.

In addition, further research is needed to determine the optimal UVA fluence and time.

For more articles in this issue of Ophthalmology Times Conference Briefclick here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.